FANNIN ADVISORY, LLC

Thesis

FANNIN ADVISORY, LLC, operating as Fannin Innovation Studio, is a Houston-based venture capital firm and product development group established in 2005. The firm specializes in advancing early-stage pharmaceutical and medical device assets, focusing on therapeutic, medical device, and diagnostic technologies originating from leading academic investigators across the United States. Fannin's strategy involves a hybrid approach, acting as both the management team and an early investor, collaborating with academic inventors to develop technologies, often leveraging grant funding alongside investor capital. This model aims to address a perceived gap in commercialization for life science innovations, particularly in regions like Houston, which possess strong research institutions but may lack the extensive commercialization infrastructure found in established biotech hubs. Fannin's investment thesis centers on developing early-stage bioscience technologies into commercial assets. The firm focuses on the life sciences sector, specifically in therapeutics, medical devices, and diagnostics. Their preference is for early-stage technologies, often stemming from academic research. Fannin operates as an Exempt Reporting Adviser (ERA), indicating a focus on venture capital funds and private funds, with assets under management in the United States below $150 million. As of June 2026, Fannin had $270 million invested across programs, with $79 million from grant funding and $191 million from investors. The firm's focus is on early-stage development, advancing programs from initial ideas through preclinic

Related lists

• Pre-seed Healthcare investors
• Seed-stage Healthcare investors
• Series A Healthcare investors